KDM1A and acute myeloid leukemia: Upon the initial description of TCP as an irreversible inhibitor of LSD1 (65), many TCP derivatives with increased selectiveness over MAOs and/or decreased toxicity toward normal erythrocytes have been generated, and a handful of them is currently tested in clinical trials for AML (see Table 1) as well as other neoplastic diseases (15).